ED Pde 5i denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for ed pde5i are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Your PDE5 Inhibitor as Not FDA-Approved

A not-FDA-approved denial in the context of PDE5 inhibitors almost always reflects one of three situations: the prescription was written for a specific indication, formulation, or patient population for which that particular agent does not have FDA approval; the product ordered is a compounded formulation that by definition lacks an FDA-approved new drug application (NDA); or there is a coding or prior-authorization submission error that caused Cigna's system to associate the request with an unapproved use. Pinpointing the exact basis is essential before drafting your appeal.

## Why This Denial Is Appealable

If the denial is based on a submission error or a misclassification of the indication, a corrected prior-authorization submission may resolve it without a formal appeal. If the use is genuinely off-label, most insurer policies — including Cigna's — allow coverage of off-label uses that are supported by a major recognized drug compendium or by guidelines from an established professional medical society. Your prescriber's documentation of the evidence basis for the prescribed use is the linchpin. For compounded formulations, the appeal argument must address why a commercially available FDA-approved alternative is not clinically adequate.

## Federal Appeal Framework

ACA Section 2719 entitles you to external review by an accredited Independent Review Organization (IRO) once Cigna's internal process is exhausted. ERISA Section 503 provides full-and-fair review rights for employer-sponsored plans. The window to request external review is approximately 4 months from the final internal denial. Expedited review (72 hours) is available when delay would seriously jeopardize your health.

## Concrete Appeal Steps and Timeline

1. Clarify the exact denial basis — request the clinical review criteria Cigna applied and determine whether the issue is indication, formulation, or a submission error. 2. Obtain the FDA prescribing label for the requested agent and confirm the labeled indication(s). 3. If off-label use: gather compendium listings (e.g., relevant drug compendia recognized by CMS or state law) or professional society guidelines supporting the use. 4. File the internal appeal within the deadline on your EOB, attaching the FDA label and any compendium or guideline support. 5. Escalate to the IRO if internal appeal is denied.

## Documentation to Gather

• Diagnosis confirmation: Chart notes with a precise diagnosis code and clinical description matching the intended use.
• FDA label: Current prescribing information showing approved indications and the relationship (or difference) to the prescribed use.
• Compendium or guideline evidence: For off-label use, the specific compendium entry or guideline recommendation supporting this application.
• Prescriber medical-necessity letter: A letter that identifies the evidence basis, explains why the requested agent is appropriate, and addresses any FDA-approval status concerns directly.
• Criteria-mapping table: Pull Cigna's clinical policy for this drug, list every requirement, and document the chart evidence satisfying each criterion.